PACB: Pacific Biosciences of California, Inc. Stock

by  •  • Comments Off on PACB: Pacific Biosciences of California, Inc. Stock

SIC 3826 – Laboratory Analytical Instruments

Valuation
Market Cap ($M) 482.68
Enterprise Value ($M) 740.24
Book Value ($M) 507.79
Book Value / Share 1.73
Price / Book 0.95
NCAV ($M) -256.64
NCAV / Share -0.87
Price / NCAV -1.88

Profitability (mra)
Return on Invested Capital (ROIC) -0.26
Return on Assets (ROA) -0.18
Return on Equity (ROE) -0.44

Liquidity (mrq)
Quick Ratio 11.19
Current Ratio 12.69

Balance Sheet (mrq) ($M)
Current Assets 497.21
Assets 1,261.65
Liabilities 753.85
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 154.01
Operating Income -290.66
Net Income -308.65
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
12-10 13G Millennium Management Llc
11-26 13G Softbank Group Corp 7.50
11-14 13G/A Madrone Capital Partners, Llc 9.90 27.50
11-14 13G Edmond De Rothschild Asset Management (france) 7.50
11-12 13G/A Vanguard Group Inc 6.47 0.00
2024-02-12 13G/A Nikko Asset Management Americas, Inc. 4.93 -6.82
2024-02-09 13G/A Jackson Square Partners, LLC 3.63 -35.32
2024-02-05 13G/A Sumitomo Mitsui Trust Holdings, Inc. 4.93 -6.82
2024-01-29 13G/A ARK Investment Management LLC 12.90 34.30
2024-01-24 13G/A BlackRock, Inc. 9.20 32.96

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPO
2024-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 o TRANSITION REPORT PU
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 o TRANSITION REPORT P
2024-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 o TRANSITION REPORT PURSUA

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-21 5,254,980 12,306,324 42.70
2025-02-20 7,152,919 17,808,378 40.17
2025-02-19 4,730,597 16,358,189 28.92
2025-02-18 5,108,650 18,375,628 27.80

(click for more detail)

Similar Companies
MLAB – Mesa Laboratories, Inc. NAUT – Nautilus Biotechnology, Inc.
NVMI – Nova Ltd. ROP – Roper Technologies, Inc.
SEER – Seer, Inc.


Financial data and stock pages provided by
Fintel.io